文献速递肝病消化道肿瘤与早癌

下一代抗精神病药阿立哌唑用于肝细胞癌化学预防

Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole.
PubMed 文献 · Hepatology · 2026-03-13

肝细胞癌(HCC)全球疾病负担重且缺乏预防策略,本研究鉴定口服非典型抗精神病药阿立哌唑为HCC化学预防候选药物。临床肝组织分析显示阿立哌唑靶点表达于成纤维细胞、巨噬细胞和上皮癌细胞,且与纤维化肝病和HCC相关。在MASH诱导HCC大鼠模型中,阿立哌唑通过调节纤维化相关通路和炎症预防肝病进展和HCC发生;机制上通过调节肝成纤维细胞和巨噬细胞表型发挥抗纤维化和抗炎作用,并通过抑制cMET和ERK通路及干扰线粒体功能阻止肿瘤起始和减少细胞增殖。患者来源肿瘤球实验显示阿立哌唑调节肿瘤微环境免疫应答。结论提示阿立哌唑是临床相关的HCC化学预防方法。

要点

  • 阿立哌唑靶点在肝成纤维细胞、巨噬细胞和上皮癌细胞表达,与纤维化肝病和HCC相关。
  • MASH诱导HCC大鼠模型中阿立哌唑预防肝病进展和HCC发生。
  • 机制涉及抗纤维化、抗炎、抑制cMET/ERK通路和干扰线粒体功能。

核心结论

  • 阿立哌唑治疗是临床相关的HCC化学预防方法。

研究设计与样本

  • 临床肝组织分析、MASH诱导HCC大鼠模型、癌细胞模型扰动研究和患者来源肿瘤球实验。

主要发现

  • 临床肝组织中阿立哌唑靶点表达于成纤维细胞、巨噬细胞和上皮癌细胞,且靶基因表达与纤维化肝病和HCC相关。
  • MASH诱导HCC大鼠模型中阿立哌唑通过调节纤维化相关通路和炎症预防肝病进展和HCC发生。
  • 阿立哌唑通过调节肝成纤维细胞和巨噬细胞表型发挥抗纤维化和抗炎作用。
  • 癌细胞模型中阿立哌唑通过抑制cMET和ERK通路及干扰线粒体功能阻止肿瘤起始和减少细胞增殖。
  • 患者来源肿瘤球中阿立哌唑调节肿瘤微环境免疫应答。

临床怎么用

  • 阿立哌唑可能作为HCC化学预防的候选药物,尤其针对纤维化肝病和MASH相关HCC高风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is a major global health burden, ranking sixth in incidence and third in cancer-related mortality. Despite therapeutic advances, treatment options for advanced liver disease and HCC are limited, and strategies to prevent HCC development are lacking. To address the urgent need for preventive strategies, we identified aripiprazole, an oral atypical antipsychotic, as a candidate for HCC chemoprevention. APPROACH AND RESULTS: Analyses of clinical liver tissues showed that aripiprazole targets are expressed in different liver cell compartments, including fibroblasts, macrophages, and epithelial cancer cells, and that target gene expression is associated with fibrotic liver diseases and HCC. In a rat model of MASH-induced HCC induced by choline-deficient L -amino acid-defined high-fat diet, aripiprazole prevents liver disease progression and HCC development by modulating fibrogenesis-related pathways and inflammation. Mechanistically, aripiprazole exerts antifibrogenic and anti-inflammatory effects by modulating the phenotype of liver fibroblasts and macrophages. Moreover, perturbation studies in cancer cell models showed that aripiprazole prevents tumor initiation and reduces cell proliferation via inhibition of the cMET and ERK pathways and perturbation of mitochondrial functions. Finally, treatment of patient-derived tumor spheroids demonstrated that aripiprazole modulates immune responses in the tumor microenvironment. CONCLUSIONS: Collectively, these findings suggest that treatment with aripiprazole is a clinically relevant approach for HCC chemoprevention.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Slović N, Mishra S, Paul S, et al. Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole. Hepatology. 2026. PMID: 41838879. doi:10.1097/HEP.0000000000001719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。